Mycobacterium africanum

Last updated

Mycobacterium africanum
Scientific classification
Domain:
Bacteria
Phylum:
Actinomycetota
Class:
Actinomycetia
Order:
Mycobacteriales
Family:
Mycobacteriaceae
Genus:
Mycobacterium
Species:
M. africanum
Binomial name
Mycobacterium africanum
Castets et al. 1969, [1] ATCC 25420

Mycobacterium africanum is a species of Mycobacterium that is most commonly found in West African countries, where it is estimated to cause up to 40% of pulmonary tuberculosis. [2] The symptoms of infection resemble those of M. tuberculosis.

Contents

It is a member of the Mycobacterium tuberculosis complex. [3]

Taxonomy

There are seven major lineages in the Mycobacterium tuberculosis complex (MTBC), with lineages 5 and 6 classified as Mycobacterium africanum. MTBC lineage 5 is M. africanum type 1, West African 1 (MAF1), and is classified based on a characteristic deletion of Region of Differentiation (RD) 711. MAF1 is commonly found around the Gulf of Guinea. MTBC lineage 6 is also known as M. africanum type 1, West African 2 (MAF2), and is classified based on a deletion of RD702. MAF2 is prevalent in Western Africa. M. africanum type 2, East African, was previously recognized as a strain of Mycobacterium africanum; it was recently reclassified as Mycobacterium tuberculosis genotype "Uganda" in a sublineage of MTBC lineage 4. [4]

History

M. africanum was first described as a subspecies within the MTBC, with phenotypic characteristics intermediate between M. tuberculosis and M. bovis, based on biochemical testing by Castets in 1968. Early genetic analysis showed that it was distinct from M. tuberculosis due to a genomic RD9 deletion and distinct GyrB nucleotide sequence, and distinct from M. bovis due to an intact RD12 and RD4. [5]

Microbiology

M. africanum is grown in pyruvate-containing media under low oxygen conditions, and forms characteristic "dysgonic" colonies. Unlike M. tuberculosis, M. africanum shows catalase activity, is nitrate negative, and is susceptible to thiopene-2-carboxylic acid hydrazide (TCH) and pyrazinamide (PZA). M. africanum is also slower growing than M. tuberculosis, typically taking 10 weeks to develop colonies rather than 3 to 4 for M. tuberculosis. [6]

Epidemiology

M. africanum is most commonly found in West African countries. [7] It is an infection of humans only and is spread by an airborne route from individuals with open cases of disease.

It is not fully understood why the distribution of M. africanum is limited to West Africa, with only sporadic cases found in other regions. [8] Phylogenetic evidence shows that M. africanum branched at an early stage from modern Mtb lineages in America, Europe and Asia. Some research suggests that M. africanum is adapted to west African populations. M. africanum may be being outcompeted by other Mtb lineages in other regions; however, genetic studies have found no difference in the number of virulence genes or genetic diversity between M. tuberculosis and M. africanum. No animal reservoir has been identified for Mycobacterium africanum despite having been found various wild animals. [9]

It has a similar degree of infectivity to the regular M. tuberculosis organism but is less likely to progress to clinical disease in an immunocompetent individual. [10] However, M. africanum is more likely to progress from infection to causing disease in an HIV positive patient. In countries where M. africanum is endemic, it represents an important opportunistic infection of the later stages of HIV disease. [11]

Pathogenesis

It is not fully understood how the genetic differences between M. africanum and M. tuberculosis give rise to the lower pathogenicity of the former. However, it is known that the Region of Difference 9 (RD9) is lacking in M. africanum but present in M. tuberculosis. [12]

M. africanum also has notable differences in lipid catabolism and metabolism. Additionally, virulence pathways such as the dosR/Rv0081 regulon or ESAT-6 regulation are disrupted in M. africanum. [13]

Treatment

Because of the similar symptoms and different growth conditions between Mycobacterium tuberculosis and africanum, culture methods are unreliable for diagnosis. Molecular biology-based genotyping has improved identification. In particular, "spoligotyping" or "spacer oligonucleotide typing", is a rapid polymerase chain reaction-based method for genotyping strains in the MTBC. Recently, lateral flow rapid tests have been developed based on the mpt64 antigen found in all members of the MTBC. [14]

M. africanum has a lower rate of progression from latency to active disease than M. tuberculosis. M. africanum tuberculosis is treated with an identical regime to tuberculosis caused by M. tuberculosis. The overall rate of cure is similar, but as more M. africanum patients are likely to be HIV positive, they may have higher mortality from other HIV-related disease. [15]

Type strain

ATCC 25420 = CIP 105147

Related Research Articles

<span class="mw-page-title-main">BCG vaccine</span> Vaccine primarily used against tuberculosis

Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). It is named after its inventors Albert Calmette and Camille Guérin. In countries where tuberculosis or leprosy is common, one dose is recommended in healthy babies as soon after birth as possible. In areas where tuberculosis is not common, only children at high risk are typically immunized, while suspected cases of tuberculosis are individually tested for and treated. Adults who do not have tuberculosis and have not been previously immunized, but are frequently exposed, may be immunized, as well. BCG also has some effectiveness against Buruli ulcer infection and other nontuberculous mycobacterial infections. Additionally, it is sometimes used as part of the treatment of bladder cancer.

<span class="mw-page-title-main">Tuberculosis</span> Infectious disease

Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but it can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis. Around 10% of latent infections progress to active disease which, if left untreated, kill about half of those affected. Typical symptoms of active TB are chronic cough with blood-containing mucus, fever, night sweats, and weight loss. It was historically referred to as consumption due to the weight loss associated with the disease. Infection of other organs can cause a wide range of symptoms.

<i>Mycobacterium tuberculosis</i> Species of pathogenic bacteria that causes tuberculosis

Mycobacterium tuberculosis, also known as Koch's bacillus, is a species of pathogenic bacteria in the family Mycobacteriaceae and the causative agent of tuberculosis. First discovered in 1882 by Robert Koch, M. tuberculosis has an unusual, waxy coating on its cell surface primarily due to the presence of mycolic acid. This coating makes the cells impervious to Gram staining, and as a result, M. tuberculosis can appear weakly Gram-positive. Acid-fast stains such as Ziehl–Neelsen, or fluorescent stains such as auramine are used instead to identify M. tuberculosis with a microscope. The physiology of M. tuberculosis is highly aerobic and requires high levels of oxygen. Primarily a pathogen of the mammalian respiratory system, it infects the lungs. The most frequently used diagnostic methods for tuberculosis are the tuberculin skin test, acid-fast stain, culture, and polymerase chain reaction.

<i>Mycobacterium</i> Genus of bacteria

Mycobacterium is a genus of over 190 species in the phylum Actinomycetota, assigned its own family, Mycobacteriaceae. This genus includes pathogens known to cause serious diseases in mammals, including tuberculosis and leprosy in humans. The Greek prefix myco- means 'fungus', alluding to this genus' mold-like colony surfaces. Since this genus has cell walls with a waxy lipid-rich outer layer that contains high concentrations of mycolic acid, acid-fast staining is used to emphasize their resistance to acids, compared to other cell types.

<i>Mycobacterium leprae</i> Bacterium that causes leprosy

Mycobacterium leprae is one of the two species of bacteria that cause Hansen’s disease (leprosy), a chronic but curable infectious disease that damages the peripheral nerves and targets the skin, eyes, nose, and muscles.

<i>Mycobacterium bovis</i> Species of bacterium

Mycobacterium bovis is a slow-growing aerobic bacterium and the causative agent of tuberculosis in cattle. It is related to Mycobacterium tuberculosis, the bacterium which causes tuberculosis in humans. M. bovis can jump the species barrier and cause tuberculosis-like infection in humans and other mammals.

<span class="mw-page-title-main">Tropical medicine</span> Interdisciplinary branch of medicine

Tropical medicine is an interdisciplinary branch of medicine that deals with health issues that occur uniquely, are more widespread, or are more difficult to control in tropical and subtropical regions.

<span class="mw-page-title-main">Buruli ulcer</span> Infectious tropical disease

Buruli ulcer is an infectious disease characterized by the development of painless open wounds. The disease is limited to certain areas of the world, most cases occurring in Sub-Saharan Africa and Australia. The first sign of infection is a small painless nodule or area of swelling, typically on the arms or legs. The nodule grows larger over days to weeks, eventually forming an open ulcer. Deep ulcers can cause scarring of muscles and tendons, resulting in permanent disability.

<span class="mw-page-title-main">Opportunistic infection</span> Infection caused by pathogens that take advantage of an opportunity not normally available

An opportunistic infection is an infection caused by pathogens that take advantage of an opportunity not normally available. These opportunities can stem from a variety of sources, such as a weakened immune system, an altered microbiome, or breached integumentary barriers. Many of these pathogens do not necessarily cause disease in a healthy host that has a non-compromised immune system, and can, in some cases, act as commensals until the balance of the immune system is disrupted. Opportunistic infections can also be attributed to pathogens which cause mild illness in healthy individuals but lead to more serious illness when given the opportunity to take advantage of an immunocompromised host.

A syndemic or synergistic epidemic is the aggregation of two or more concurrent or sequential epidemics or disease clusters in a population with biological interactions, which exacerbate the prognosis and burden of disease. The term was developed by Merrill Singer in the early 1990s to call attention to the synergistic nature of the health and social problems facing the poor and underserved. Syndemics develop under health disparity, caused by poverty, stress, or structural violence and are studied by epidemiologists and medical anthropologists concerned with public health, community health and the effects of social conditions on health.

<span class="mw-page-title-main">Subclinical infection</span> Nearly or completely asymptomatic infection

A subclinical infection—sometimes called a preinfection or inapparent infection—is an infection by a pathogen that causes few or no signs or symptoms of infection in the host. Subclinical infections can occur in both humans and animals. Depending on the pathogen, which can be a virus or intestinal parasite, the host may be infectious and able to transmit the pathogen without ever developing symptoms; such a host is called an asymptomatic carrier. Many pathogens, including HIV, typhoid fever, and coronaviruses such as COVID-19 spread in their host populations through subclinical infection.

Mycobacterium avium complex is a group of mycobacteria comprising Mycobacterium intracellulare and Mycobacterium avium that are commonly grouped because they infect humans together; this group, in turn, is part of the group of nontuberculous mycobacteria. These bacteria cause Mycobacterium avium-intracellulare infections or Mycobacterium avium complex infections in humans. These bacteria are common and are found in fresh and salt water, in household dust and in soil. MAC bacteria usually cause infection in those who are immunocompromised or those with severe lung disease.

Mycobacterium canettii, a novel pathogenic taxon of the Mycobacterium tuberculosis complex (MTBC), was first reported in 1969 by the French microbiologist Georges Canetti, for whom the organism has been named. It formed smooth and shiny colonies, which is highly exceptional for the MTBC. It was described in detail in 1997 on the isolation of a new strain from a 2-year-old Somali patient with lymphadenitis. It did not differ from Mycobacterium tuberculosis in the biochemical tests and in its 16S rRNA sequence. It had shorter generation time than clinical isolates of M. tuberculosis and presented a unique, characteristic phenolic glycolipid and lipo-oligosaccharide. In 1998, Pfyffer described abdominal lymphatic TB in a 56-year-old Swiss man with HIV infection who lived in Kenya. Tuberculosis caused by M. canettii appears to be an emerging disease in the Horn of Africa. A history of a stay to the region should induce the clinician to consider this organism promptly even if the clinical features of TB caused by M. canettii are not specific. The natural reservoir, host range, and mode of transmission of the organism are still unknown.

<span class="mw-page-title-main">Multidrug-resistant tuberculosis</span> Medical condition

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB).

A reverse zoonosis, also known as a zooanthroponosis or anthroponosis, is a pathogen reservoired in humans that is capable of being transmitted to non-human animals.

The Royal Society Africa Prize has been awarded by the Royal Society since 2006 to African-based researchers at the start of their career who are making innovative contributions to the biological sciences in Africa. £60,000 is awarded as a grant for the recipient to carry out a research project that is linked to an African centre of scientific excellence, normally a University or equivalent research centre, and a further £5,000 is given directly to the prizewinner.

The Mycobacterium tuberculosis complex is a genetically related group of Mycobacterium species that can cause tuberculosis in humans or other animals.

Dorothy Yeboah-Manu is a microbiologist and Professor at the Noguchi Memorial Institute for Medical Research at the University of Ghana. She studies host and pathogen interactions and epidemiology. She won the 2018 Royal Society Africa Prize.

<i>Mycobacterium ulcerans</i> Species of bacterium

Mycobacterium ulcerans is a species of bacteria found in various aquatic environments. The bacteria can infect humans and some other animals, causing persistent open wounds called Buruli ulcer. M. ulcerans is closely related to Mycobacterium marinum, from which it evolved around one million years ago, and more distantly to the mycobacteria which cause tuberculosis and leprosy.

Martin Antonio is an Ghanaian Biologist who is Principal Investigator at the Medical Research Council Unit at London School of Hygiene and Tropical Medicine. He is Director of the World Health Organization Centre for New Vaccines Surveillance and leads the West and Central Africa Regional Reference Laboratory for Invasive Bacterial Diseases.

References

  1. ↑ Castets, M.; Rist, N.; Boisvert, H. (1969). "La variété africaine du bacille tuberculeux humain". Médecine d'Afrique Noire. 16: 321–2.
  2. ↑ de Jong, B.; Antonio, M.; Gagneux, S. (28 September 2010). "Mycobacterium africanum—Review of an Important Cause of Human Tuberculosis in West Africa". PLOS Neglected Tropical Diseases. 4 (9): e744. doi: 10.1371/journal.pntd.0000744 . PMC   2946903 . PMID   20927191.
  3. ↑ Vasconcellos SE, Huard RC, Niemann S, et al. (2010). "Distinct genotypic profiles of the two major clades of Mycobacterium africanum". BMC Infect. Dis. 10: 80. doi: 10.1186/1471-2334-10-80 . PMC   2859774 . PMID   20350321.
  4. ↑ de Jong, B.; Antonio, M.; Gagneux, S. (28 September 2010). "Mycobacterium africanum—Review of an Important Cause of Human Tuberculosis in West Africa". PLOS Neglected Tropical Diseases. 4 (9): e744. doi: 10.1371/journal.pntd.0000744 . PMC   2946903 . PMID   20927191.
  5. ↑ Yeboah-Manu, Dorothy; de Jong, Bouke C.; Gehre, Florian (2017). "The Biology and Epidemiology of Mycobacterium africanum". In Sebastien Gagneux (ed.). Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control. Advances in Experimental Medicine and Biology. Vol. 1019. Cham: Springer International Publishing. pp. 117–133. doi:10.1007/978-3-319-64371-7_6. ISBN   978-3-319-64371-7. PMID   29116632.
  6. ↑ Yeboah-Manu, Dorothy; de Jong, Bouke C.; Gehre, Florian (2017). "The Biology and Epidemiology of Mycobacterium africanum". In Sebastien Gagneux (ed.). Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control. Advances in Experimental Medicine and Biology. Vol. 1019. Cham: Springer International Publishing. pp. 117–133. doi:10.1007/978-3-319-64371-7_6. ISBN   978-3-319-64371-7. PMID   29116632.
  7. ↑ de Jong, B.; Antonio, M.; Gagneux, S. (28 September 2010). "Mycobacterium africanum—Review of an Important Cause of Human Tuberculosis in West Africa". PLOS Neglected Tropical Diseases. 4 (9): e744. doi: 10.1371/journal.pntd.0000744 . PMC   2946903 . PMID   20927191.
  8. ↑ de Jong, B.; Antonio, M.; Gagneux, S. (28 September 2010). "Mycobacterium africanum—Review of an Important Cause of Human Tuberculosis in West Africa". PLOS Neglected Tropical Diseases. 4 (9): e744. doi: 10.1371/journal.pntd.0000744 . PMC   2946903 . PMID   20927191.
  9. ↑ Yeboah-Manu, Dorothy; de Jong, Bouke C.; Gehre, Florian (2017). "The Biology and Epidemiology of Mycobacterium africanum". In Sebastien Gagneux (ed.). Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control. Advances in Experimental Medicine and Biology. Vol. 1019. Cham: Springer International Publishing. pp. 117–133. doi:10.1007/978-3-319-64371-7_6. ISBN   978-3-319-64371-7. PMID   29116632.
  10. ↑ de Jong, B.; Hill, P.; Aiken, A.; Awine, T.; Martin, A.; Adetifa, I.; Jackson-Sillah, D.; Fox, A.; DeRiemer, K.; Gagneux, S.; Borgdorff, M.; McAdam, K.; Corrah, T.; Small, P.; Adegbola, R. (2008). "Progression to Active Tuberculosis, but Not Transmission, Varies by Mycobacterium tuberculosis Lineage in The Gambia". The Journal of Infectious Diseases. 198 (7): 1037–1043. doi:10.1086/591504. PMC   2597014 . PMID   18702608.
  11. ↑ de Jong, B.; Hill, P.; Brookes, R.; Otu, J.; Peterson, K.; Small, P.; Adegbola, R. (14 October 2005). "Mycobacterium africanum: a new opportunistic pathogen in HIV infection?". AIDS. 19 (15): 1714–1715. doi:10.1097/01.aids.0000185991.54595.41. PMID   16184053.
  12. ↑ Brosch R, Gordon SV, Marmiesse M, et al. (March 2002). "A new evolutionary scenario for the Mycobacterium tuberculosis complex". Proc. Natl. Acad. Sci. U.S.A. 99 (6): 3684–9. Bibcode:2002PNAS...99.3684B. doi: 10.1073/pnas.052548299 . PMC   122584 . PMID   11891304.
  13. ↑ Yeboah-Manu, Dorothy; de Jong, Bouke C.; Gehre, Florian (2017). "The Biology and Epidemiology of Mycobacterium africanum". In Sebastien Gagneux (ed.). Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control. Advances in Experimental Medicine and Biology. Vol. 1019. Cham: Springer International Publishing. pp. 117–133. doi:10.1007/978-3-319-64371-7_6. ISBN   978-3-319-64371-7. PMID   29116632.
  14. ↑ Yeboah-Manu, Dorothy; de Jong, Bouke C.; Gehre, Florian (2017). "The Biology and Epidemiology of Mycobacterium africanum". In Sebastien Gagneux (ed.). Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control. Advances in Experimental Medicine and Biology. Vol. 1019. Cham: Springer International Publishing. pp. 117–133. doi:10.1007/978-3-319-64371-7_6. ISBN   978-3-319-64371-7. PMID   29116632.
  15. ↑ de Jong, B.; Hill, P.; Brookes, R.; Otu, J.; Peterson, K.; Small, P.; Adegbola, R. (14 October 2005). "Mycobacterium africanum: a new opportunistic pathogen in HIV infection?". AIDS. 19 (15): 1714–1715. doi:10.1097/01.aids.0000185991.54595.41. PMID   16184053.

Bibliography

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.